If you or a loved one were diagnosed with a meningioma brain tumor after taking Depo-Provera or Depo-SubQ Provera injections, you may be entitled to recover compensation from a Depo-Provera lawsuit case or settlement claim.
A team of drug injury lawyers and class action attorneys is investigating potential Depo-Provera lawsuit and settlement cases of women who suffered from a meningioma brain tumor after using Depo-Provera or Depo-SubQ Provera.
Depo-Provera and Depo-SubQ Provera (medroxyprogesterone acetate) are progestin hormone birth control shots or contraceptive medication injections used to prevent pregnancy (and/or treat endometriosis) by suppressing ovulation (preventing the ovaries from releasing eggs) and by thickening the cervical mucus to prevent sperm from getting to an egg. Depo-Provera is typically given via a 150 mg intramuscular injection in the gluteal (buttocks) or deltoid (upper arm) muscle every three months.
It has been estimated that more than a million women each year in the United States use Depo-Provera and that about twenty percent of all women in the U.S. have used Depo-Provera, Depo-SubQ Provera or a generic form of the birth control medication at some point in their lifetime.
Unfortunately, according to a study in the British Medical Journal, women who used progestogen birth control medication like Depo-Provera may be at an increased risk of developing a meningioma (perhaps as much as 5.55 times more likely to develop a meningioma tumor). Meningiomas are tumors that begin in the middle layer of tissue (arachnoid) of the membrane (meninges) surrounding the brain and spinal cord. Meningiomas can lead to complications and, in rare cases, death.
Depo-Provera Meningioma Lawsuit: Overview
- What Is a Depo-Provera Birth Control Shot?
- Who May Qualify For a Depo-Provera Lawsuit or Settlement?
- What Is The Depo-Provera Lawsuit About?
- What Health Issues May Be Linked to Depo-Provera Shots?
- What is a Meningioma Brain Tumor Tumor?
- Are Depo-Provera Users More Likely to Develop Meningiomas?
- What Are The Signs and/or Symptoms of Meningiomas?
- Are There Medical Treatments for Meningioma Tumors?
- What Companies Have Been Sued Over Depo-Provera?
- What is The Status of The Depo Provera Meningioma Lawsuits?
- Can I Recover Compensation From a Depo-Provera Lawsuit?
- Is There A Time Limit To Filing a Depo-Provera Lawsuit?
- Request A Free Case Review From A Depo-Provera Injury Lawyer
Depo-Provera Lawsuit & Settlement Cases
Depo-Provera lawsuit and settlement cases potentially being investigated include claims involving women who were diagnosed with meningioma brain tumors after using Depo-Provera, Depo-SubQ Provera and/or certain generic birth control shots, including:
- Depo-Provera
- Depo-SubQ Provera
- Depo Provera
- Depo-Provera Contraceptive Injection (DPCI)
- Depo Provera IM
- Depo medroxyprogesterone acetate (DMPA)
- Medroxyprogesterone acetate (MPA or IM MPA)
- Depo-SubQ Provera 104
- Greenstone Medroxyprogesterone
- Greenstone MPA
- Prasco Medroxyprogesterone
- Prasco MPA
If you or someone you love suffered from a meningioma brain tumor after using depo provera, you may be eligible to seek compensation from a depo-provera lawsuit or settlement case.
Depo-Provera Injury Lawsuit Complaint
Plaintiffs in the Depo-Provera lawsuits have alleged, among other things, that they suffered from meningioma and brain tumor complications or injury after using Depo-Provera and that defendants knew or should have known that Depo-Provera may cause meningiomas but did not provide an adequate warning about the risk of intracranial meningioma or the need for monitoring for resultant symptoms.
The Depo-Provera lawsuit complaints have asserted claims for, among other things, negligence, negligent failure to warn and design defect, strict liability (failure to warn and design defect), negligent misrepresentation fraudulent misrepresentation, and breach of warranty (express and implied). Plaintiffs in Depo Provera lawsuits seek to recover compensatory damages (including compensation for physical pain, mental suffering, inconvenience, loss of the enjoyment of life, expenses, incidental past and future expenses, medical expenses, and loss of earnings and earning capacity), statutory damages, punitive damages, and/or attorneys’ fees and costs, among others.
Companies Sued Over Depo-Provera Injuries
Defendants in Depo-Provera lawsuits have included manufacturers, sellers and/or distributors of brand-name Depo-Provera or Depo-SubQ Provera and/or authorized generics, including, for example:
- Pfizer
- Pharmacia & Upjohn Company LLC
- Greenstone LLC
- Viatris
- Prasco LLC d/b/a Prasco Labs
Depo-Provera Lawsuit and Settlement Updates
Recent updates about Depo-Provera lawsuits and settlements include:
- October 2025: As of October 1, 2025, there were 1,222 Depo-Provera injury claims pending in the Depo-Provera MDL litigation.
- September 2025: On September 30, 2025 the Court held a hearing on Pfizer’s motion for summary judgment that asserts that federal preemption bars plaintiff’s failure to warn claims.
- May 2025: On May 6, 2025 the Court entered a Pretrial Order governing the identification of deficiencies with respect to Plaintiff Proof of Use/Injury Questionnaires and threshold documentary proof of use of Depo-Provera and meningioma diagnoses. On May 12, 2025 the Court issued Pretrial Order governing the identification of deficiencies in Plaintiff Depo-provera Complaints.
- March 2025: On March 13, 2025 the Court issued a Pretrial Order allowing Dep-provera lawsuit cases to be directly filed in the Depo-Provera MDL. The Court also issued several other pre-trial orders governing depositions, protective orders, production of documents, and appointment of attorneys to various leadership positions within the Depo-provera MDL.
- February 2025: On February 7, 2025 the JPML issued an order establishing a Depo Provera MDL and transferring federal Depo-Provera lawsuits to the United States District Court for the Northern District of Florida (Judge Casey Rodgers) for coordinated or consolidated pretrial proceedings. The JPML found that the depo-provera lawsuits involved common questions of fact, such as “whether Depo-Provera causes meningioma, whether defendants knew of the alleged risk of meningioma, whether they failed to adequately warn of this risk, and whether defendants failed to promote safer alternatives, such as Depo-SubQ Provera 104, which plaintiffs argue is safer due to its lower dose of medroxyprogesterone acetate and its administration through subcutaneous injection (rather than the intramuscular injection used for Depo-Provera).” The JPML also determined that centralization would “eliminate duplicative discovery; prevent inconsistent pretrial rulings; and conserve the resources of the parties, their counsel, and the judiciary.”
- November 2024: On November 26, 2024 Plaintiffs in the Depo-Provera lawsuits filed a motion with the Judicial Panel on Multi-District Litigation (“JPML”), captioned as In Re: Depo-Provera (Depot Medroxy-progesterone Acetate) Products Liability Litigation, MDL Case No. 3140, seeking to transfer federal Depo Provera injury cases into a multi-district litigation pursuant to 28 U.S.C. § 1407 for consolidation and coordination of pretrial proceedings.
Depo-Provera Meningioma Lawsuit Cases: Brain Tumors
Depo-Provera meningioma lawsuit cases potentially being investigated include claims involving women who, after using Depo-Provera, Depo-SubQ Provera or a generic form of the birth control shot, were diagnosed with a meningioma brain tumor, including:
- Meningioma
- Brain tumor
- Primary brain tumor
- Intracranial meningioma
- Intercranial meningioma
- Cranial meningioma
- Brain meningioma
- Meninges tumor
- Arachnoid tumor (not arachnoid cyst)
- Convexity meningioma
- Falcine meningioma
- Parasagittal meningioma
- Intraventricular meningioma
- Skull base meningioma
- Sphenoid wing meningioma
- Olfactory groove meningioma
- Posterior fossa/petrous meningioma
- Suprasellar meningioma
- Recurrent meningioma
- Foramen magnum meningioma
- Meningothelial meningioma
- Fibrous meningioma
- Psammomatous meningioma
- Angiomatous meningioma
- Secretory meningioma
- Other meningiomas or meningiomata
- Other Depo-Provera injury lawsuit cases
Meningiomas are the most common type of primary brain tumor, accounting for about 40 percent of all primary brain tumors. According to the National Organization for Rare Disorders (NORD), about 42,000 people in the United States are diagnosed with meningioma each year.
Meningiomas are classified as either Grade I meningiomas (slow growing, low grade tumors, representing about 80 percent of all meningioma cases), Grade II meningiomas (faster growing, mid grade tumors such as chordoid and clear cell meningiomas, accounting for about 18 percent of all meningioma cases) or Grade III meningiomas (fastest growing and malignant or cancerous tumors, including anaplastic meningiomas such as papillary meningiomas and rhabdoid meningiomas, comprising about 2 percent of all meningioma cases).
Although the majority of meningiomas are benign, intracranial meningioma tumors can grow until they are very large, putting pressure on areas surrounding the affected areas of the brain or spinal cord.
Studies Linking Depo-Provera Use to Meningioma
Several recent scientific studies and publications have found a potential link between the use of Depo-Provera birth control injections (injectable medroxyprogesterone acetate, dMPA) and an increased risk of developing meningioma brain tumors.
For example, a study published in The BMJ in 2024 that involved 18,061 women living in France who had intracranial surgery for meningioma between January 1, 2009 and December, 31 2018 found that prolonged use (one year or more) of medroxyprogesterone acetate injections resulted in a 5.55-fold increase risk of developing an intracranial meningioma compared to a control group. See Roland N, Neumann A, Hoisnard L, Duranteau L, Froelich S, Zureik M et al. Use of progestogens and the risk of intracranial meningioma: national case-control study, BMJ 2024; 384 :e078078 doi:10.1136/bmj-2023-078078.
Another study published in Cancers (Basel) in 2024 that involved 117,503 meningioma cases, found a 53% increased chance of developing cerebral meningioma for those who used medroxyprogesterone acetate (OR 1.53, 95% CI 1.40–1.67), which risk became even stronger with longer duration of medroxyprogesterone acetate use: a 2.5-fold increased odds for exposure durations greater than 3 years (OR 2.50, 95% CI 2.06–3.04). See, Russell L Griffin, The Association between Medroxyprogesterone Acetate Exposure and Meningioma, Cancers (Basel), 2024 Sep; 16(18): 3326.
In yet another study published in Expert Opinion on Drug Safety in 2025, researchers found that among women using medroxyprogesterone acetate (MPA) for more than one year, the adjusted incidence rate ratio (IRR) for meningiomas was 3.55 (95% CI: 1.85–6.85), indicating a significantly higher risk compared to women using oral contraceptives containing ethinylestradiol-levonorgestrel EE-LNG. See, Frey, C., Sodhi, M., Fatehi, M., Kezouh, A., & Etminan, M. (2025). Use of medroxyprogesterone acetate and risk of meningiomas: a comparative safety study, Expert Opinion on Drug Safety, 1–4, https://doi.org/10.1080/14740338.2025.2526787
Meningioma Signs & Symptoms
Signs and symptoms of meningioma can include:
- Seizures
- Blurred vision
- Seeing double
- Headaches (worse in morning)
- Loss of balance
- Weakness in arm(s)
- Weakness in leg(s)
- Numbness
- Hearing loss
- Ringing in ears
- Memory issues
- Loss of sense of smell
- Difficulty speaking
- Slurred speech
- Confusion
- Trouble focusing
- Aphasia
- Cognitive difficulties
- Dizziness
- Personality change
- Palsy
- Pain
- Other meningioma symptoms or signs
Procedures and tests used by neurologists, oncologists, radiologists and other physicians to diagnose meningiomas can include a patient history, physical examination, neurological exam, brain scans (MRI with contrast, CT scans, X-rays, etc.) to check for “dural tail signs” or meningeal signs (i.e., thickening of the dura mater, the outer layer of the meninges), biopsy of tumor tissue, among others.
Meningioma Medical Treatment
Treatment for meningiomas can include surgery (e.g., a maximum gross total surgical resection), radiation treatment (external beam radiotherapy, brachytherapy, stereotactic radiosurgery SRS or Gamma Knife surgery, fractionated stereotactic radiotherapy SRT, intensity-modulated radiation therapy IMRT) and chemotherapy, among others.
If not treated, meningiomas can lead to serious complications and may be life-threatening, even when benign, since they can grow and intrude on brain tissue, nerves, blood vessels and other structures.
Compensation For Depo-Provera Injuries
Plaintiffs who bring depo-provera meningioma lawsuits may be able to recover compensation for injuries they suffered, including money damages for losses incurred as a result of their having been diagnosed with meningioma brain tumors, such as:
- Compensatory damages for pain and suffering
- Loss of wages or earnings due to missed work
- Loss of future earning capacity
- Medical care expenses incurred or to be incurred
- Other out of pocket expenses
- Loss of quality or enjoyment of life
- Mental anguish/emotional distress
- Loss of consortium
- Other possible monetary damages
Time Is Limited To File A Depo-Provera Lawsuit
Deadlines called statutes of limitation and statutes of repose may limit the time that women have to file a Depo-Provera lawsuit to try to recover compensation for injuries they claim to have suffered (e.g., complications relating to meningioma brain tumors) after using Depo-Provera, Depo-SubQ Provera or medroxyprogesterone acetate.
This means that if a Depo-Provera lawsuit claim is not filed before the applicable deadline or limitations period, the injured party may be barred from ever pursuing litigation or taking legal action regarding their Depo-Provera injury claim. That is why it is important to connect with a Depo-Provera injury lawyer or attorney as soon as possible.
If you or a loved one have suffered from meningioma brain tumors after using Depo-Provera or Depo-SubQ Provera, you may be entitled to recover compensation from a Depo-Provera lawsuit case or settlement claim. Contact a drug injury lawyer to request a free case review.
*If you or a loved one are experiencing health issues, side effects or complications after taking a prescription drug or medication, we urge you to promptly consult with your doctor or physician for an evaluation.
**The listing of a company (e.g., Pfizer, Pharmacia & Upjohn Company LLC, Greenstone LLC, Viatris, Prasco) or product (e.g., Depo-Provera or Depo-SubQ Provera) is not meant to state or imply that the company acted illegally or improperly or that the product is unsafe or defective; rather only that an investigation may be, is or was being conducted to determine whether legal rights have been violated.
***The use of any trademarks, tradenames or service marks is solely for product identification and/or informational purposes.
Fill out the form to request a free attorney review.